5-methoxy-1-methyl-1H-benzo[d]imidazole-2-thiol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-methoxy-1-methyl-1H-benzo[d]imidazole-2-thiol
• 英文别名: 6-methoxy-3-methyl-1H-benzimidazole-2-thione
• 化学式: C₉H₁₀N₂OS
• 分子量: 194.257
• InChiKey: ZDXVDGBQLMIQFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  56.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-methoxy-1-methyl-1H-benzo[d]imidazole-2-thiol 在 双氧水 作用下， 以 甲醇 、 2,2,2-三氟乙醇 、 水 为溶剂， 反应 24.0h， 生成 methyl 3-((5-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl) sulfinyl)propanoate
  参考文献：
  名称：

  使用卤代戊鎓盐催化磺酸根阴离子对映体选择性烷基化为手性杂环亚砜

  摘要：

  我们报道了卤化戊二烯作为相转移催化剂，用于将亚硫酸根阴离子不对称烷基化为具有高对映选择性（高达99％ee）和产率（高达99％）的各种亚砜。这种方法可以获取可能与强氧化剂或有机金属试剂不兼容的对映体富集的杂环亚砜。计算研究表明，涉及多个非共价相互作用，例如卤素键和非经典氢键。

  DOI：

  10.1002/anie.201407512
• 作为产物：
  描述：

  1-(2-Amino-4-methoxy-phenyl)-1-methyl-3-phenyl-thiourea 、 原甲酸三乙酯 、 1,4-二氧六环 生成 5-methoxy-1-methyl-1H-benzo[d]imidazole-2-thiol
  参考文献：
  名称：

  LUGOSI P.; AGAI B.; HORNYAK G., PERIOD. POLYTECHN. CHEM. ENG. 1975, 19, NO 4, 307-316

  摘要：

  DOI：

文献信息

• LUGOSI P.; AGAI B.; HORNYAK G., PERIOD. POLYTECHN. CHEM. ENG. 1975, 19, NO 4, 307-316
  作者：LUGOSI P.、 AGAI B.、 HORNYAK G.

  DOI：——

  日期：——
• METHOD OF PREPARING LITHOGRAPHIC PRINTING PLATE
  申请人：Taguchi Yoshinori

  公开号：US20100081771A1

  公开（公告）日：2010-04-01

  A method for preparing a lithographic printing plate includes treating a lithographic printing plate precursor including a hydrophilic support and an image-forming layer containing the following (i) to (iii) with an aqueous solution having a buffering ability: (i) a binder polymer comprising a repeating unit having a structure represented by the following formula (1); (ii) an ethylenically unsaturated compound; and (iii) a polymerization initiator, P-L-(CO 2 H) n (1) wherein P represents a part constituting a main chain skeleton of the polymer, L represents an (n+1) valent connecting group, and n represents an integer of 1 or more.
• BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF
  申请人：TRINUERO

  公开号：US20220016099A1

  公开（公告）日：2022-01-20

  The present invention provides a pharmaceutical composition for preventing and treating central nervous system (CNS) diseases, diabetes and complications thereof, the pharmaceutical composition comprising, as an active ingredient, a benzimidazole or benzoxazole derivative having the structure of chemical formula 1 or a pharmaceutically acceptable salt thereof. The benzimidazole or benzoxazole derivative used as an active ingredient in the pharmaceutical composition of the present invention can, via an Nrf2 activation mechanism caused by the Keap1-Nrf2-ARE pathway and via an activation pathway of glutamate transporters such as GLT-1/EAAT and GLAST, inhibit oxidative damage in the central nervous system and the pancreas while inducing production of an antioxidant such as glutathione, thereby maximizing the effect of treating central nervous system diseases, diabetes and complications thereof.
• [EN] CATALYSTS FOR MAKING CHIRAL HETEROCYCLIC SULFOXIDES<br/>[FR] CATALYSEURS POUR LA PRÉPARATION DE SULFOXYDES HÉTÉROCYCLIQUES CHIRAUX
  申请人：UNIV NANYANG TECH

  公开号：WO2016039691A1

  公开（公告）日：2016-03-17

  Compounds of formula (I): wherein R and A- are defined herein as a catalyst for making chiral heterocyclic sulfoxides and a method of producing enantioenriched sulfoxide in the presence of the said compounds.
• [EN] BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF<br/>[FR] BENZIMIDAZOLE OU DÉRIVÉS DE BENZIMIDAZOLE PERMETTANT DE PRÉVENIR ET DE TRAITER UNE MALADIE DU SYSTÈME NERVEUX CENTRAL, LE DIABÈTE ET LEURS COMPLICATIONS<br/>[KO] 중추신경계 질환, 당뇨병 및 이의 합병증의 예방 및 치료를 위한 벤즈이미다졸 또는 벤족사졸 유도체
  申请人：TRINUERO

  公开号：WO2020116742A1

  公开（公告）日：2020-06-11

  본 발명은 화학식 1의 구조를 갖는 벤즈이미다졸 또는 벤족사졸 유도체 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 중추신경계(central nervous system, CNS) 질환, 당뇨병 및 이의 합병증의 예방 및 치료용 약학적 조성물을 제공한다. 본 발명의 약학적 조성물은 유효성분으로 사용된 벤즈이미다졸 또는 벤족사졸 유도체가 Keap1-Nrf2-ARE 경로를 통한 Nrf2의 활성화 메커니즘 및 GLT-1/EAAT, GLAST 등과 같은 글루타메이트 수송체(transporter)의 활성화 경로를 통해 중추신경계 및 췌장에서의 산화적 손상을 억제하고 글루타티온과 같은 항산화물질의 생성을 유도함으로써, 중추신경계 질환, 당뇨병 및 이의 합병증의 치료 효과를 극대화할 수 있다.